Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. After the webcast, a replay will be archived on the website for at least 30 days.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.
Prof. Yuankai Shi, chief physician of...
Waverley Pharma Inc. ("Waverley Pharma" or the "Company") , a Canadian pharmaceutical company, is announcing a business update.
As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing...
Feeding Matters is proud to celebrate the 6th annual PFD Awareness Month, which is recognized around the globe. This designation, initiated by Feeding...
Korea Ginseng Corp. US (KGCUS) aka JungKwanJang held a dedicated international seminar session on "Korean Ginseng: Safety, Efficacy And Neuroprotective Insights'' at the International Conference on the Science of Botanicals (ICSB) hosted by the...